The IGNYTE continues to show promising outcomes despite negative FDA decisions.
Daniel Olson, MD, discusses the results of a phase 1 trial of brenetasfusp, a PRAME ImmTAC therapy in advanced melanoma.
APP-led benign hematology consults boost access in community oncology—cut wait times, expand capacity, and show how teams scale safely. As community oncology practices continue to face growing patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results